Red Cat (US:RCAT) Seeking Alphaยท2025-11-14 16:21Company Performance - Red Cat Holdings, Inc. (RCAT) reported a Q3 '25 EPS loss of approximately -$0.16, missing expectations by $0.07 [1] - Revenue for the same period was $9.65 million, significantly below the consensus estimate of $14.12 million [1] - The market reaction to these results was negative, leading to a decline in share prices [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, focusing on biotechnology investments [1] - The analyst's approach combines scientific expertise with financial analysis to identify promising biotechnology companies [1] - The focus is on evaluating drug candidates, competitive landscapes, clinical trial designs, and market opportunities while considering financial fundamentals [1]